Sign In
Buy GSK
$51.46
-0.0700 (-0.136%)
At Close: Aug 05, 2026
Sell AstraZeneca, says UBS, which upgrades European rivals including GSK
05:34am, Tuesday, 16'th Jan 2024
UBS analysts shook up their ratings of European drugmakers, including making a double-downgrade of AstraZeneca and a double-upgrade of U.K. rival GSK.
Is GSK worth £20 a share? This broker seems to thinks so
09:31am, Monday, 15'th Jan 2024
Shore Capital's recent research note on GSK PLC (LSE:GSK, NYSE:GSK) paints an optimistic picture for the pharmaceutical giant, underlining reasons for maintaining a 'Buy' recommendation with a raised
GSK still a top pick in pharma sector for Deutsche Bank
09:49am, Wednesday, 10'th Jan 2024
GSK has received a healthy price target upgrade from analysts at Deutsche Bank, which has the UK pharma as a top pick in a sector with a mixed outlook in 2024. “Top-down, our sector view remains neu
GSK to Buy Private Biotech, Strengthen Respiratory Pipeline
09:01am, Wednesday, 10'th Jan 2024
GSK's proposed acquisition of Aiolos is set to add the latter's long-acting anti-TSLP monoclonal antibody, AIO-001, to GSK's broad portfolio of respiratory products.
iTeos: Readouts From TIGIT And Adenosine Pathway Inhibitors Makes This A Must Watch
08:01am, Wednesday, 10'th Jan 2024
iTeos: Readouts From TIGIT And Adenosine Pathway Inhibitors Makes This A Must Watch
International Wide-Moat Stocks On Sale - The January 2024 Heat Map
06:04pm, Tuesday, 09'th Jan 2024
International Wide-Moat Stocks On Sale - The January 2024 Heat Map
GSK plc (GSK) 42nd Annual JP Morgan Healthcare Conference (Transcript)
02:38pm, Tuesday, 09'th Jan 2024
GSK plc (GSK) 42nd Annual JP Morgan Healthcare Conference (Transcript)
GSK Boosts Respiratory Portfolio with $1.4 Billion Aiolos Bio Acquisition
02:15pm, Tuesday, 09'th Jan 2024
British pharmaceutical giant GSK PLC on Tuesday announced a $1.4 billion deal to acquire Aiolos Bio Inc., boosting its respiratory portfolio.
GSK strong finish expected, says Barclays
07:06am, Tuesday, 09'th Jan 2024
GSK PLC (LSE:GSK, NYSE:GSK) should deliver better than expected fourth-quarter results on January 31, according to Barclays, amid heightened expectations driven by the robust performance of its RSV v
GSK to buy asthma drug developer for up to $1.4 billion in pipeline push
05:19am, Tuesday, 09'th Jan 2024
GSK on Tuesday said it had struck a deal to acquire asthma drug developer Aiolos Bio for up to $1.4 billion, as the British pharmaceutical giant pushes forward with plans to bolster its development pi
GSK to pay up to $1.4bn for respiratory acquisition
03:07am, Tuesday, 09'th Jan 2024
GSK PLC (LSE:GSK, NYSE:GSK) has moved to bolster its respiratory franching with the acquisition of Aiolos Bio for up to $1.4bn. It is paying an upfront $1 billion and $400 million based on certain re
GSK Buys Asthma-Focused Aiolos
02:35am, Tuesday, 09'th Jan 2024
GSK said it has bought Aiolos Bio for an upfront consideration of $1 billion, with the potential for an additional $400 million.
GSK to acquire Aiolos Bio in $1.4 bln deal
02:08am, Tuesday, 09'th Jan 2024
British drugmaker GSK on Tuesday said it would acquire clinical-stage biopharmaceutical firm Aiolos Bio for a $1 billion upfront payment and up to $400 million in certain success-based regulatory mile
GSK (GSK) Rises But Trails Market: What Investors Should Know
07:34pm, Monday, 08'th Jan 2024
The latest trading day saw GSK (GSK) settling at $39.64, representing a +1.1% change from its previous close.
Why Glaxo (GSK) is Poised to Beat Earnings Estimates Again
01:32pm, Friday, 05'th Jan 2024
Glaxo (GSK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
